Abstract
BACKGROUND: The majority of mental health problems are non-psychotic (e.g., depression, anxiety, and phobias). Art therapy is currently being used in the UK for a variety of mental health conditions. This cost-effectiveness analysis formed part of a health technology assessment for the National Institute for Health Research. OBJECTIVES: To conduct a cost-utility analysis of studies evaluating cost effectiveness of art therapy and identify areas in need of further research
Highlights
On the basis of available evidence, our model suggests it may be cost-effective to treat patients with lower severity of symptoms than have been included in the majority of existing RCTs
Our findings indicate that commercially-produced products were no more effective than free-to-use Computerised cognitive behaviour therapy (cCBT) programmes
Neither Beating the Blues (BtB) or MoodGYM appeared cost-effective compared to usual general practitioner care (UGPC) alone
Summary
To estimate the cost-effectiveness of paliperidone palmitate (PLAI), a once-monthly long-acting injectable (LAI) atypical antipsychotic, compared to the most common antipsychotic strategies in France. Quality-adjusted-life-years (QALYS) and number of relapses were assessed over five years based on three-month cycles, and discounted at 4%, from a health insurance perspective. Relapse rates were derived from hospitalisation risks based on French real-life data in order to capture the adherence effects. Results: PLAI was the less costly LAI and associated with an incremental cost-effectiveness ratio (ICER) of € 1,988/QALY gained and € 2,267/relapse avoided versus OO. RLAI and PLAI were associated with the highest number of QALYs Conclusions: This analysis is the first to assess the cost-effectiveness of antipsychotics based on French observational data.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
